T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy

A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers -; is low, despite a Food and Drug Administration warning.

12 Jun 2024

Enhancing CAR-T cell therapy with biodegradable scaffolds

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers. Six approved CAR-T products have been administered to more than 20,000 people, and more than 500 clinical trials are underway.

12 Jun 2024

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

12 Jun 2024

How Epstein-Barr virus shapes immune responses in multiple sclerosis

Study found that EBV-specific immune responses in MS patients showed higher IgG titers and cell-mediated reactions to EBV antigens compared to healthy controls, suggesting a complex role of EBV in MS development.

9 Jun 2024

Gene therapy trial: restored hearing in children with hereditary deafness

The safety and effectiveness of binaural adeno-associated virus 1 (AAV1)-human otoferlin (hOTOF) therapy in five children with autosomal recessive deafness 9 (DFNB9).

7 Jun 2024

‘Artificial lymph node’ shows potential to treat cancer

Johns Hopkins Medicine scientists say they have developed an artificial lymph node with the potential to treat cancer, according to a new study in mice and human cells.

6 Jun 2024

Exploring the biology behind maternal mental health disorders

Pregnancy and new motherhood transform a woman's body as well as her life. While this is often a joyous time, it can sometime lead to mental health disorders, most often anxiety and depression.

6 Jun 2024

Researchers identify a potential metabolic target for cancer immunotherapy

Researchers at the VIB-KU Leuven Center for Cancer Biology have identified a potential target for cancer immunotherapy.

6 Jun 2024

UC San Diego Health launches personalized immunotherapy for metastatic melanoma

UC San Diego Health is the first hospital system in the region to offer a new immunotherapy treatment for metastatic melanoma.

4 Jun 2024

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Advanced clear cell renal cell carcinoma (ccRCC) is a deadly form of kidney cancer with few treatment options; even with new immunotherapies, only around one in 10 patients ultimately survive.

4 Jun 2024

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

Clinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).

3 Jun 2024

Canagliflozin enhances senescent cell clearance, improving aging-related conditions

Whether sodium-glucose co-transporter 2 (SGLT2) inhibitors induce senolysis.

3 Jun 2024

Breakthrough CAR T therapy and shorter targeted therapy durations offer hope for patients with leukemia

The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy obecabtagene autoleucel (obe-cel) achieved durable remissions in 40% of patients with relapsed or refractory B-ALL without a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX clinical trial presented today by Elias Jabbour, M.D., professor of Leukemia.

31 May 2024

Single infusion of engineered T-cells achieves lasting asthma remission in mice

Researchers demostrate that durable asthma remission can be achieved with engineered and long-lived CAR T-cell treatment in mice.

31 May 2024

How tight binding between immune cells dictates T cell cancer-fighting ability

Immunotherapy, treatments that reinvigorate immune cells' anti-cancer activity or reprogram T cells to target cancer, has shown promise in treating leukemias but has not yet been realized in solid tumors.

30 May 2024

New paper reveals the broad potential of TNIK as a therapeutic target for some aging-related diseases

A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence (AI)- and robotics-powered clinical stage drug discovery company Insilico Medicine ("Insilico") and ETH Zurich reveals the broad potential of TNIK as a therapeutic target for some of the most pervasive aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer's.

28 May 2024

New subset of T cells may enhance cancer immunotherapy

A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies.

28 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.

21 May 2024

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

From ERS Genomics 21 May 2024